Login to Your Account

Other News To Note

Friday, August 19, 2011
NPS Pharmaceuticals Inc., of Bedminster, N.J., submitted the chemistry, manufacturing and controls section of its new drug application (NDA) for Gattex (teduglutide), a recombinant analogue of human glucagon-like peptide 2, for use in short bowel syndrome (SBS). The rolling NDA follows positive data from a 24-week Phase III study testing Gattex's ability to reduce parenteral nutrition and intravenous fluid requirements in adults with SBS.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription